Sex differences in incidence of drug therapy in Sweden in 2010 by pharmacological group
| ATC | Pharmacological group | PAT/1000 PYs | RR (95% CI) | Age-adjusted RR (95% CI) | |
|---|---|---|---|---|---|
| Men | Women | Women/men | Women/men | ||
| J02 | Antimycotics for systemic use | 2.28 | 13.23 | 5.80 (5.68 to 5.92) | 5.49 (5.38 to 5.60) |
| H03 | Thyroid therapy | 1.55 | 5.77 | 3.72 (3.62 to 3.81) | 3.49 (3.40 to 3.58) |
| M05 | Drugs for treatment of bone diseases | 0.97 | 3.98 | 4.11 (3.98 to 4.24) | 3.49 (3.38 to 3.60) |
| N02C | Antimigraine preparations | 1.89 | 4.99 | 2.64 (2.57 to 2.70) | 2.67 (2.61 to 2.74) |
| A08 | Antiobesity preparations | 0.55 | 1.41 | 2.57 (2.45 to 2.69) | 2.60 (2.48 to 2.72) |
| H01 | Pituitary and hypothalamic hormones and analogues | 0.99 | 2.45 | 2.47 (2.38 to 2.55) | 2.48 (2.40 to 2.57) |
| A12 | Mineral supplements | 5.82 | 14.85 | 2.55 (2.52 to 2.59) | 2.21 (2.18 to 2.24) |
| J05 | Antivirals for systemic use | 4.60 | 8.53 | 1.85 (1.82 to 1.89) | 1.80 (1.77 to 1.83) |
| P01 | Antiprotozoals | 9.38 | 16.83 | 1.80 (1.77 to 1.82) | 1.79 (1.76 to 1.81) |
| B03 | Antianaemic preparations | 12.28 | 23.72 | 1.93 (1.91 to 1.95) | 1.70 (1.68 to 1.72) |
| N06A | Antidepressants | 15.35 | 24.71 | 1.61 (1.59 to 1.62) | 1.52 (1.51 to 1.54) |
| L02 | Endocrine therapy | 1.37 | 2.43 | 1.78 (1.73 to 1.84) | 1.52 (1.48 to 1.56) |
| N05B | Anxiolytics | 17.90 | 28.41 | 1.59 (1.57 to 1.60) | 1.47 (1.46 to 1.48) |
| M03 | Muscle relaxants | 4.50 | 6.67 | 1.48 (1.46 to 1.51) | 1.46 (1.44 to 1.49) |
| A07 | Antidiarrhoeals, intestinal anti-inflammatory/antiinfective agents | 6.68 | 10.27 | 1.39 (1.37 to 1.41) | 1.39 (1.37 to 1.41) |
| A02 | Drugs for acid related disorders | 25.47 | 37.35 | 1.47 (1.46 to 1.48) | 1.38 (1.37 to 1.39) |
| N05C | Hypnotics and sedatives | 18.90 | 26.94 | 1.43 (1.41 to 1.44) | 1.32 (1.31 to 1.34) |
| S01B | Anti-inflammatory agents | 9.27 | 13.71 | 1.48 (1.46 to 1.50) | 1.29 (1.27 to 1.31) |
| H02 | Corticosteroids for systemic use | 21.36 | 28.28 | 1.32 (1.31 to 1.33) | 1.27 (1.26 to 1.28) |
| N03 | Antiepileptics | 4.76 | 6.29 | 1.32 (1.30 to 1.35) | 1.25 (1.22 to 1.27) |
| L04 | Immunosuppressants | 1.43 | 1.80 | 1.26 (1.22 to 1.30) | 1.23 (1.20 to 1.27) |
| J01 | Antibacterials for systemic use | 126.14 | 153.73 | 1.22 (1.21 to 1.22) | 1.21 (1.20 to 1.21) |
| R03 | Drugs for obstructive airway diseases | 27.19 | 32.11 | 1.18 (1.17 to 1.19) | 1.19 (1.18 to 1.20) |
| N04 | Anti-Parkinson drugs | 1.67 | 2.26 | 1.35 (1.31 to 1.39) | 1.19 (1.15 to 1.22) |
| S02 | Otologicals | 3.39 | 4.04 | 1.19 (1.17 to 1.22) | 1.17 (1.14 to 1.19) |
| N02A | Opioids | 39.55 | 48.30 | 1.22 (1.21 to 1.23) | 1.14 (1.14 to 1.15) |
| C03 | Diuretics | 10.63 | 14.35 | 1.35 (1.33 to 1.37) | 1.14 (1.13 to 1.15) |
| S03 | Ophthalmological and otological preparations | 18.43 | 21.41 | 1.16 (1.15 to 1.17) | 1.14 (1.13 to 1.15) |
| G04BD | Urinary antispasmodics | 2.63 | 3.33 | 1.27 (1.24 to 1.30) | 1.10 (1.08 to 1.13) |
| N05A | Antipsychotics | 3.27 | 4.03 | 1.23 (1.21 to 1.26) | 1.07 (1.05 to 1.10) |
| N06D | Antidementia drugs | 0.91 | 1.38 | 1.52 (1.46 to 1.58) | 1.07 (1.03 to 1.11) |
| B01 | Antithrombotic agents | 15.05 | 17.48 | 1.16. (1.15 to 1.7) | 1.05 (1.04 to 1.06) |
| C07 | β blocking agents | 12.16 | 13.61 | 1.12 (1.11 to 1.13) | 1.02 (1.01 to 1.03) |
| S01E | Antiglaucoma preparations and miotics | 1.90 | 2.15 | 1.13 (1.10 to 1.16) | 0.96 (0.93 to 0.98) |
| C09C+D | Angiotensin II antagonists and combinations | 6.18 | 6.42 | 1.04 (1.02 to 1.05) | 0.95 (0.93 to 0.96) |
| C08 | Calcium channel blockers | 10.35 | 10.72 | 1.04 (1.02 to 1.05) | 0.93 (0.92 to 0.94) |
| C01A | Cardiac glycosides | 1.09 | 1.24 | 1.14 (1.10 to 1.18) | 0.86 (0.82 to 0.89) |
| C09A+B | ACE-inhibitors and combinations | 14.28 | 13.11 | 0.92 (0.91 to 0.93) | 0.83 (0.82 to 0.84) |
| C10 | Lipid modifying agents | 13.01 | 11.28 | 0.87 (0.86 to 0.88) | 0.81 (0.80 to 0.82) |
| A10 | Drugs used in diabetes | 4.83 | 3.79 | 0.79 (0.77 to 0.80) | 0.73 (0.72 to 0.75) |
| N06B | Psychostimulants | 2.36 | 1.57 | 0.67 (0.65 to 0.69) | 0.70 (0.68 to 0.72) |
| C01D | Vasodilators used in cardiac diseases | 8.34 | 6.93 | 0.83 (0.82 to 0.84) | 0.69 (0.68 to 0.70) |
| M04 | Antigout preparations | 2.71 | 1.44 | 0.53 (0.51 to 0.55) | 0.44 (0.42 to 0.45) |
Crude and age-adjusted relative differences for included ATC groups. The following pharmacological groups were excluded from the table due to sex-specific indications; G02 Other gynaecologicals (dispensed to 5.33 PAT/1000 PYs in women and 0.03 PAT/1000 PYs in men), G03A Hormonal contraceptives (dispensed to 42.09 PAT/1000 PYs in women and 0.04 PAT/1000 PYs in men), G03C Estrogens (dispensed to 16.44 PAT/1000 PYs in women and 0.03 PAT/1000 PYs in men), G03D Progestogens (dispensed to 11.20 PAT/1000 PYs in women and 0.01 PAT/1000 PYs in men), G03F Progestogens and estrogens in combination (dispensed to 2.56 PAT/1000 PYs in women and 0.00 PAT/1000 PYs in men), G04C Drugs used in benign prostatic hypertrophy (dispensed to 0.20 PAT/1000 PYs in women and 7.34 PAT/1000 PYs in men) and G04BE Drugs used in erectile dysfunction (dispensed to 0.03 PAT/1000 PYs in women and 10.16 PAT/1000 PYs in men).
The relative differences were calculated with women as the numerator and men as the denominator. The table is sorted starting with the group with the largest age-adjusted sex difference. PAT/1000 PYs=number of patients (men or women) per 1000 patient-years. N=4 649 014 men and 4 691 668 women.
ATC, Anatomical Therapeutic Chemical; RR, risk ratio.